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Abstract
Background. The strategies of perioperative bridging anticoagulation in orthopedic surgical patients during 
oral anticoagulation (OAC) therapy with vitamin K antagonists (VKA) vary from center to center.
Objectives. The aim of this single-center study was to assess the risk of bleeding and thromboembolic events 
(TEs) in bridged patients on VKA who underwent orthopedic surgery due to trochanteric or hip fracture.
Material and methods. The retrospective study included 64 patients (mean age: 80 years) who re-
ceived VKA for at least 3 months prior to orthopedic procedure. All subjects were bridged with enoxaparin 
(40 mg once a day). The control group (n = 69) comprised of age-, sex- and procedure-matched patients 
operated on for the same indications, but with neither a history of VKA therapy nor perioperative bridging 
anticoagulation.
Results. Severe postoperative bleeding occurred in 19 (29.7%) patients from the VKA group and in 13 
(18.8%) controls (p = 0.16). Within the VKA group, intertrochanteric fractures (52.6%) and femoral neck 
fractures (47.4%) occurred more often in patients with bleeding than other lower extremity fractures 
(0%; p = 0.03). Severe adverse events (SAEs) were more common in the VKA group than in the controls 
(12.5% vs 1.5%; p = 0.01). Patients from the VKA group did not differ from the controls in the incidence 
of TEs (6.3% vs 8.9%; p = 0.31). No intrahospital mortality was documented.
Conclusions. Prophylactic administration of enoxaparin is a common strategy of bridging anticoagulation 
in a hospital setting. This approach does not seem to be associated with an increase in thromboembolic risk 
nor higher risk of bleeding in orthopedic patients who received VKA preoperatively.
Key words: anticoagulation, low molecular weight heparin, vitamin K antagonists, bridging therapy, tro-
chanteric and hip neck fracture surgery
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Introduction
A large proportion of older persons from many coun-
tries receive oral anticoagulation (OAC) with vitamin K 
antagonists (VKA); one example is the UK, where VKA 
are prescribed to approx. 1% of older patients.1,2 Noticeably, 
such individuals are more prone to osteoporosis, an estab-
lished risk factor for femoral neck fracture.
Fixation of  femoral neck and trochanteric fractures 
is a relatively common surgical procedure in older patients, 
associated with high comorbidity and mortality rates.3–5 
According to the literature, hip and trochanteric surger-
ies carry a 4% risk of perioperative mortality and a 3.2% 
risk of thromboembolism.6 Despite the implementation 
of thromboprophylaxis, pulmonary embolism (PE) is still 
a common cause of perioperative mortality, accounting 
for approx. 10% of deaths among older orthopedic inpa-
tients.7 A retrospective analysis including a total of 3,082 
patients who underwent hip, knee or spine surgeries docu-
mented major perioperative bleeding in 5.3% of the cases.8 
In another study, the incidence of thromboembolic events 
(TEs) and mortality rates in patients undergoing total hip 
or knee arthroplasties were estimated at 4% and approx. 
0.7%, respectively.9 A large proportion of patients being 
referred to an orthopedic treatment are at increased risk 
of venous thromboembolism (VTE), stroke or systemic 
embolism, due to the presence of atrial fibrillation (AF), 
mechanical heart valves or recurrent VTE; such individu-
als require long-term OAC therapy with VKA or new gen-
eration anticoagulants.
Appropriate anticoagulation treatment can be challeng-
ing in patients operated on in an emergency setting; while 
discontinuation of OAC may increase the risk of TEs, its 
maintenance may predispose to bleeding-related complica-
tions.10 In a study of 1,884 patients with AF, in whom VKA 
treatment has been interrupted prior to an elective surgery 
or other invasive procedure, forgoing bridging anticoag-
ulation was not inferior to perioperative bridging with 
low-molecular-weight-heparin (LMWH) in the prevention 
of arterial thromboembolism, while it decreased the risk 
of major bleeding.11 Nevertheless, bridging therapy with 
LMWH should be applied to minimize thromboembolic 
risk during the anticoagulation-free interval, and in line 
with current guidelines, LMWH at a  therapeutic dose 
is preferred in surgical patients at increased risk of bleed-
ing and thromboembolic complications.12 Perioperative 
administration of LMWH as a component of bridging 
anticoagulation may be associated with an increased risk 
of bleeding and severe adverse events (SAEs), such as in-
tracranial hemorrhage with subsequent major disability 
or even death.13–17 The ORBIT-AF study included a total 
7,372 patients receiving OAC therapy; among them 665 
individuals were given a short-acting anticoagulant to re-
duce the risk of TEs during a temporary discontinuation 
of OAC. In this study, bridging anticoagulation was associ-
ated with an increased risk of bleeding and other adverse 
events after the interruption of OAC.18 A meta-analysis 
including a total of 7,118 bridged and 5,160 nonbridged 
patients demonstrated unequivocally that heparin bridg-
ing is associated with a 3–4% risk of major bleeding and 
13–15% risk of overall bleeding complications in the peri-
operative period.17
To the best of our knowledge, bridging anticoagulation 
and its outcomes in Polish orthopedic inpatients receiving 
a long-term treatment with VKA has been a subject of only 
a few previous studies. The aim of this single-center study 
was to assess the risk of bleeding and TEs and the impact 
of bridging anticoagulation in patients on VKA who under-
went orthopedic surgery due to trochanteric or hip fracture.
Material and methods
Patients
The retrospective study included all consecutive pa-
tients receiving VKA, who underwent surgical fixation 
of trochanteric or femoral neck fracture at the Depart-
ment of Orthopedics, St. Lucas Hospital in Tarnów, Poland, 
in the period of 2012–2014. The study received the ap-
proval of the bioethics committee. A total of 4,453 pa-
tients were treated surgically for trochanteric or hip frac-
tures during the study period, and individuals on VKA 
therapy represented 1.4% of this population. The VKA 
group included 24 (37.5%) patients with intertrochanteric 
fractures, 24 (37.5%) with femoral neck fractures, 2 (3.1%) 
with shank fractures, and 14 (21.9%) with ankle fractures. 
Only the patients who received bridging anticoagulation 
in line with the hospital protocol (n = 64) were included 
in the analysis. According to the protocol, anticoagulation 
therapy was discontinued on the day of admission, and 
enoxaparin (40 mg per day) was given 1 day prior to the or-
thopedic procedure and 1 day thereafter. All patients were 
informed about possible risks of discontinuation of OAC 
and implementation of bridging therapy beforehand, and 
gave their informed consent to this approach. The control 
group (n = 69) was comprised of age-, sex- and procedure-
matched patients operated on for the same indications, but 
with neither a history of OAC with VKA nor periopera-
tive bridging anticoagulation. Lower extremity fractures 
were diagnosed based on a physical examination, as well 
as pelvic and femoral radiograms.
Patients who received anticoagulation therapy with 
non-vitamin K or direct oral anticoagulants (NOACs) 
and/or individuals subjected to conservative treatment 
of the fracture were excluded from the study. Information 
about past and present comorbidities was extracted from 
patients’ medical histories. Postoperative bleeding was 
classified as severe whenever the patient required a trans-
fusion of at least 2 units of packed red blood cells. Severe 
adverse events were defined as major bleeding or serious 
cardiovascular events, such as myocardial infarction (MI), 
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stroke, VTE, or dyspnea after the surgery. The interrup-
tion of anticoagulation therapy was 2–7 days. Depending 
on the type of fracture, the study subjects underwent to-
tal hip arthroplasty or interlocking fixation of trochan-
teric fracture with the  intramedullary GAMMA nail. 
In the case of total hip arthroplasty, the patient was placed 
on the nonfractured side; a straight incision, approx. 15 cm 
in length, was made, and either Bipolar or Exeter prosthe-
sis (Stryker Howmedica, Kalamazoo, USA) with acrylic 
cement was implanted from a posterolateral approach. 
The mean duration of the procedure, defined as the time 
between the  incision and placement of the  last suture, 
was 70–80 min. Intertrochanteric fractures were treated 
by intramedullary stabilization with the GAMMA nail. 
This minimally invasive procedure was associated with 
only a mild bleeding. The mean time of the surgery was 
about 60 min.
Laboratory tests
Blood samples for laboratory testing were collected 12 h 
prior to the surgery and 8 h post-surgery. All laboratory 
tests were conducted at a local hospital laboratory using 
standardized assays.
Statistical analysis
Normal distribution of continuous variables was veri-
fied with the Kolmogorov-Smirnov test. Statistical char-
acteristics of normally distributed variables are presented 
as means ± standard deviations (SD). Otherwise, the re-
sults are presented as medians (interquartile ranges (IQR)). 
Prior to statistical analysis, non-normal data was subject-
ed to a logarithmic (log 10) transformation. Depending 
on the distribution type, the Student’s t-test or the Mann-
Whitney U  test was used for  intergroup comparisons 
of continuous variables. Distributions of categorical vari-
ables are presented as numbers and percentages, and were 
compared using χ2 test. The  results of  statistical tests 
were considered significant whenever a 2-sided p-value 
was lower than 0.05. All calculations were carried out with 
STATISTICA v. 9.1 (StatSoft Inc., Tulsa, USA).
Results
Preoperative period
The  study included 133 patients with trochanteric 
or femoral neck fractures (47 men and 86 women) with 
a mean age of 80 years. Baseline characteristics of the study 
subjects are summarized in Table 1. None of the controls 
had indications for VKA therapy. Indications for OAC 
in the VKA group included AF (n = 56; 87.5%), mechani-
cal valve replacement (n = 7; 10.9%) and a previous VTE 
(n = 1; 1.6%). A total of 34 patients (53.1%) were treated with 
warfarin and 30 (46.9%) with acenocumarol. Subjects from 
the VKA group had higher body weight and body mass 
index (BMI) than the controls, and more often received 
aspirin, β-blockers, angiotensin converting enzyme (ACE) 
inhibitors, calcium channel blockers, and proton pump 
inhibitors. Moreover, they presented with significantly 
higher preoperative international normalized ratios (INR), 
activated partial thromboplastin time (APTT), red cell 
distribution width (RDW), and creatinine levels, as well 
as  with significantly lower platelet counts and fasting 
blood glucose concentrations, than the controls. The study 
groups did not differ significantly in terms of the main 
diagnoses, comorbidities and medications (Table 1).
Postoperative period
During the postoperative period, severe bleeding oc-
curred in  19 (29.7%) patients from the  VKA group 
and in 13 (18.8%) controls (Table 2). Severe adverse events 
were more common in the VKA group than in controls 
(n = 8; 12.5% vs n = 1; 1.5%; p = 0.01). No significant in-
tergroup differences were found in the incidence of car-
diovascular complications, such as MI, stroke and VTE, 
as well as in terms of other complications (Table 2). Pa-
tients on VKA received more fresh frozen plasma units 
and required longer preoperative hospitalization. Within 
the VKA group, intertrochanteric fractures and femoral 
neck fractures occurred more often in patients with bleed-
ing than with lower extremity fractures (intertrochanteric 
fractures: n = 10; 52.6% vs n = 14; 31.1%; femoral neck frac-
tures: n = 9; 47.4% vs n = 15; 33.3%; other fractures: n = 0 vs 
n = 16; 34.6% in patients with hemorrhage and in patients 
without hemorrhage, respectively; p = 0.03) (Table 3). Pa-
tients from the VKA group who experienced perioperative 
hemorrhage did not differ from other subjects from this 
group in terms of their basic characteristics, medications 
and laboratory parameters (Table 3).
Discussion
The findings presented here demonstrate that patients 
operated on due to trochanteric or femoral neck fractures, 
both with prophylactic LMWH bridging and without it, 
were not at increased risk for bleeding and TEs.
Risk of bleeding is a major concern related to bridging 
anticoagulation. Recent evidence suggests that peripro-
cedural bleeding-to-thrombosis ratio in bridged and non-
bridged patients approximates 13:1 and 5:1, respectively, 
which implies that the former group is at a considerable 
risk of bleeding.19 Indeed, according to literature, antico-
agulation-related hemorrhage is associated with increased 
morbidity and mortality, which surpasses the  benefits 
of perioperative bridging.20,21 Thromboembolic events oc-
cur rarely during periprocedural period; in contrast, bleed-
ing complications after implementation of bridging therapy 
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Table 1. Characteristics of the study subjects
Variable Overall (n = 133) VKA group (n = 64) Controls (n = 69) p-value
Age [years] 80 (72–86.5) 79.5 (72.25–86) 80 (68.5–87) 0.78
Male gender, n [%] 47 (35.3) 28 (43.8) 19 (27.5) 0.07
Body weight [kg] 70.0 (63.0–80.0) 72.0 (65.0–85.7) 69.0 (61.5–76.0) 0.03
Body height [cm] 165.7 (±8.0) 165.7 (±7.5) 165.8 (±8.5) 0.92
BMI [kg/m²] 25.7 (23.2–28.4) 26.0 (23.5–30.0) 25.1 (23.0–27.5) 0.04
Current smoker, n [%] 2 (2.90) 0 (0.0) 2 (2.90) 1.00
Diagnosis
Intertrochanteric fracture, n [%] 49 (36.84) 24 (37.50) 25 (36.23) 0.76
Femoral neck fracture, n [%] 48 (36.09) 24 (37.50) 24 (34.78) –
Lower leg fracture, n [%] 7 (5.26) 2 (3.13) 5 (7.25) –
Other fracture, n [%] 29 (21.80) 14 (21.88) 15 (21.74) –
Indication for anticoagulation
VTE, n [%] 1 (0.75) 1 (1.56) 0 (0.00) 0.48
AF, n [%] 56 (42.11) 56 (87.50) 0 (0.00) <0.0001
Artificial heart valve, n [%] 7 (5.26) 7 (10.94) 0 (0.00) 0.005
Comorbidities
CHD, n [%] 71 (53.38) 40 (62.50) 31 (44.93) 0.06
MI, n [%] 16 (12.03) 11 (17.19) 5 (7.25) 0.11
Previous stroke, n [%] 11 (8.27) 6 (9.38) 5 (7.25) 0.76
Arterial hypertension, n [%] 96 (72.18) 51 (79.69) 45 (65.22) 0.08
DM, n [%] 19 (14.29) 9 (14.06) 10 (14.49) 1.00
Hyperthyroidism, n [%] 8 (6.02) 6 (9.38) 2 (2.90) 0.15
Hypothyroidism, n [%] 7 (5.26) 3 (4.69) 4 (5.80) 1.00
CKD, n [%] 8 (6.02) 4 (6.25) 4 (5.80) 1.00
COPD, n [%] 6 (4.51) 2 (3.13) 4 (5.80) 0.68
Asthma, n [%] 4 (3.01) 1 (1.56) 3 (4.35) 0.62
Superficial thrombosis, n [%] 4 (3.01) 3 (4.69) 1 (1.45) 0.35
Previous gastric ulcer, n [%] 5 (3.76) 3 (4.69) 2 (2.90) 0.67
HF, n [%] 5 (7.81) 5 (7.81) 0 (0.0) 1.00
Medications
VKA type
Acenocumarol, n [%] – 30 (46.88) 0 (0.0) –
Warfarin, n [%] – 34 (53.13) 0 (0.0) –
LMWH
Enoxaparin, n [%] 131 (98.50) 64 (100.00) 67 (97.10) 0.5
Nadroparin, n [%] 2 (2.90) 0 (0.00) 2 (1.50) –
ASA, n [%] 106 (79.70) 61 (95.31) 45 (65.22) <0.0001
β-blocker, n [%] 92 (69.70) 53 (84.13) 39 (56.52) 0.0006
ACEI, n [%] 104 (78.20) 56 (87.50) 48 (69.57) 0.02
ARB, n [%] 4 (3.01) 2 (3.13) 2 (2.90) 1.00
Aldosterone antagonist, n [%] 3 (2.26) 2 (3.13) 1 (1.45) 0.61
Calcium channel blocker, n [%] 18 (13.53) 13 (20.31) 5 (7.25) 0.04
Statin, n [%] 82 (61.65) 44 (68.75) 38 (55.07) 0.11
Fenofibrate, n [%] 20 (15.04) 12 (18.75) 8 (11.59) 0.33
Amiodarone, n [%] 2 (1.50) 2 (3.13) 0 (0.00) 0.23
Furosemide, n [%] 36 (27.07) 21 (32.81) 36 (27.07) 0.17
Metformin, n [%] 9 (6.77) 3 (4.69) 6 (8.70) 0.50
PPIs, n [%] 48 (36.09) 30 (46.88) 18 (26.09) 0.02
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are far more common and this preventive measure does 
not seem to provide an evident antithrombotic benefit.20 
Nevertheless, various forms of bridging anticoagulation 
are still commonly used in patients qualified for invasive 
procedures.20 In our study, average blood loss in bridged 
patients (3.11 g/dL of hemoglobin) tended to be greater than 
in nonbridged subjects, but the difference was insignificant. 
Blood loss in patients operated on due to intertrochanteric 
fracture or hip neck fracture was greater than in individu-
als with other types of lower extremity fractures. Probably, 
this was associated with the older age of patients with in-
tertrochanteric and hip neck fractures, and with a larger 
extent of surgical procedures performed in  this group. 
Altogether, our findings imply that prophylactic admin-
istration of enoxaparin to older patients qualified for or-
thopedic surgeries is not associated with increased risk 
of major bleeding. Nevertheless, irrespective of bridging 
anticoagulation or lack thereof, the risk of bleeding in this 
group is still high, as shown by a large proportion of our 
patients who required postoperative blood transfusions.
Beneficial effects of bridging in patients at  increased 
risk of TE are unclear, and we still lack sufficient evidence 
in this matter from well-designed clinical trials. However, 
the  results of observational studies suggest that  imple-
mentation of bridging therapy is associated with a sub-
stantial decrease in  the  incidence of  VTE events, even 
in  high-risk populations.20,22 Therefore, until adequate 
evidence from clinical trials becomes available, indi-
vidualized bridging anticoagulation therapy still should 
be considered in  patients with established risk factors 
for VTE, such as mechanical mitral valve, or acute or re-
cent VTE. Evidence from retrospective studies suggests 
that bleeding-to-thrombosis profile of bridged patients with 
implanted mechanical valves, i.e., with an established risk 
factor for TEs, may be relatively favorable.23,24 Whenever 
bridging therapy is deemed necessary, more conservative 
strategies should be considered, namely, low-dose heparin, 
administration of heparin solely in the postoperative period, 
delayed initiation of postprocedural heparin bridging, de-
layed onset of postprocedural heparin bridging, and early 
cessation of warfarin when a international normalized ratio 
(INR) value reaches 2.0 or more.25–27 Early discontinuation 
of VKA and administration of enoxaparin, 40 mg once a day, 
are a preferred bridging strategy at our department. Such 
an approach may raise some controversies, especially in pa-
tients with mitral valve prostheses. Unfortunately, the subset 
of our patients who received VKA due to the implantation 
of mechanical valves was too small to conduct a subgroup 
analysis (n = 11). Although none of these subjects developed 
a TE episode during the follow-up period, it is still unclear 
whether bridging with higher doses of LMWH or nonfrac-
tioned heparin should be recommended for patients from 
this group prior to a major surgical procedure.
In line with current recommendations, surgical treatment 
of hip fractures in older patients should be implemented 
early, optimally within 24–48 h post-admission.28 How-
ever, adherence to these guidelines can be quite challenging 
in the case of patients on VKA anticoagulation therapy; 
reversal of OAC to prevent excessive bleeding may cause 
a significant delay in a major orthopedic procedure, such 
as hip surgery.29,30 Such a delay is associated with increased 
morbidity and mortality.31 Vitamin K antagonists therapy 
can be reversed passively, by interruption of warfarin and 
waiting until INR returns to the reference range (<1.2), 
Variable Overall (n = 133) VKA group (n = 64) Controls (n = 69) p-value
NSAIDs, n [%] 6 (4.51) 5 (7.81) 1 (1.45) 0.11
Laboratory tests
INR 1.43 (1.10–2.50) 2.59 (1.79–3.33) 1.10 (1.05–1.18) <0.0001
APTT [s] 31.00 (27.65–37.85) 36.60 (31.35–44.36) 28.30 (25.60–30.80) <0.0001
FBG [g/L] 3.20 (2.90–3.57) 2.96 (2.72–3.62) 3.23 (2.99–3.56) 0.02
WBC [103/µL] 10.20 (8.00–12.85) 10.30 (8.05–13.25) 10.20 (8.00–12.50) 0.67
RBC [106/µL] 4.05 (3.40–4.38) 4.04 (3.32–4.43) 4.06 (3.55–4.37) 0.60
HGB [g/dL] 12.10 (10.35–13.35) 11.90 (9.83–13.48) 12.30 (10.80–13.30) 0.35
HCT [%] 36.90 (31.60–39.90) 36.75 (30.43–40.33) 37.10 (32.35–39.90) 0.55
RDW [%] 14.30 (13.60–15.25) 14.50 (13.83–15.80) 13.90 (13.40–14.80) 0.02
PLT [103/µL] 198.00 (155.00–255.00) 176.50 (136.50–241.50) 212.00 (172.50–260.00) 0.01
Glucose [mmol/L] 123.00 (108.75–145.00) 122.00 (110.00–138.50) 127.00 (108.00–148.00) 0.52
Creatinine [µmol/L] 74.00 (58.25–94.75) 82.00 (63.00–108.00) 71.00 (54.50–91.00) 0.01
eGFR [mL/min] 80.00 (57.50–98.00) 78.00 (55.00–94.00) 80.00 (62.00–102.25) 0.28
ACEI – angiotensin converting enzyme inhibitors; AF – atrial fibrillation; APTT – activated partial thromboplastin time; ASA – acetylsalicylic acid;  
ARB – angiotensin receptor blockers; BMI – body mass index; CHD – chronic heart disease; CKD – chronic kidney disease; COPD – chronic obstructive 
pulmonary disease; DM – diabetes mellitus; eGFR – estimated glomerular filtration rate; FBG – fibrinogen; HCT – hematocrit; HF – heart failure;  
HGB – hemoglobin; INR – international normalized ratio; PPIs – proton-pump inhibitors; LMWH – low molecular weight heparin; MI – myocardial infarction; 
NSAIDs – non-steroidal anti-inflammatory drugs; PLT – platelets; RBC – red blood cell count; RDW – red blood cell distribution width; ST – stroke;  
VKA – vitamin K antagonist; VTE – venous thromboembolism; WBC – white blood cell count.
Table 1. Characteristics of the study subjects (cont.)
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Table 2. Postoperative characteristics of the study subjects
Variable Overall (n = 133) VKA group (n = 64) Controls (n = 69) p-value
Complications
Hemorrhage, n [%] 32 (24.1) 19 (29.7) 13 (18.8) 0.16
PE/VTE, n [%] 4 (3.01) 4 (6.25) 0 (0.00) 0.05
MI, n [%] 1 (0.75) 1 (1.56) 0 (0.00) 0.48
ST, n [%] 1 (0.75) 1 (1.56) 0 (0.00) 0.48
SAEs, n [%] 9 (6.77) 8 (12.50) 1 (1.45) 0.01
Other complications, n [%] 1 (1.45) 4 (6.25) 5 (3.76) 0.20
Perioperative care
PRBCs, n [%] 33 (24.81) 19 (29.69) 14 (20.29) 0.23
PRBCs [units] 2.00 (2.00–4.00) 2.00 (2.00–4.00) 2.00 (2.00–2.50) 0.44
FFP, n [%] 19 (14.29) 11 (17.19) 11 (17.19) 0.46
FFP [units] 2.00 (2.00–2.00) 2.00 (2.00–2.00) 1.50 (1.00–2.00) 0.009
Preoperative [days] 4.00 (2.00–5.00) 4.00 (3.00–6.00) 3.00 (2.00–4.00) 0.0009
Postoperative [days] 5.00 (4.00–7.00) 6.00 (5.00–8.00) 6.00 (4.00–7.00) 0.06
Postoperative laboratory tests
INR 1.17 (1.06–1.39) 1.17 (1.06–1.39) 1.19 (1.13–1.25) 0.72
APTT [a] 29.30 (27.23–31.78) 30.40 (26.80–34.10) 29.55 (27.13–32.75) 0.36
FBG [g/L] 3.01 (2.60–3.30) 2.52 (2.37–2.98) 3.18 (2.98–3.46) <0.0001
WBC [103/µL] 9.40 (7.33–12.20) 9.60 (7.10–12.40) 8.90 (7.45–11.55) 0.48
RBC [106/µL] 3.64 (3.26–4.03) 3.64 (3.24–4.13) 3.65 (3.27–4.02) 0.86
HGB [g/dL] 10.65 (9.63–11.90) 10.70 (9.70–11.90) 10.60 (9.60–12.00) 0.86
HCT [%] 32.95 (29.43–36.30) 33.00 (29.20–36.90) 32.90 (29.55–36.05) 0.53
RDW [%] 14.60 (13.50–15.90) 15.10 (13.80–16.20) 14.30 (13.30–15.30) 0.01
PLT [103/µL] 205.00 (162.00–278.75) 198.00 (147.00–284.00) 207.00 (172.50–270.00) 0.33
APTT – activated partial thromboplastin time; FBG – fibrinogen; FFP – fresh frozen plasma; HCT – hematocrit; HGB – hemoglobin; INR – international 
normalized ratio; MI – myocardial infarction; PLT – platelets; PRBCs – packed red blood cells; PE – pulmonary embolism; RBC – red blood cell count;  
SAEs – serious adverse events; ST – stroke; VTE – venous thromboembolism; WBC – white blood cell count.
or actively, by the administration of vitamin K, fresh fro-
zen plasma, clotting factor concentrates, or a combination 
thereof. In line with current guidelines, prior to a major 
surgery, INR should be lower than 1.5.32 Our findings con-
firm that this recommendation is followed strictly in clini-
cal practice. Bleeding and neurological complications may 
be also associated with the insertion or removal of a spi-
nal or epidural catheter in an anticoagulated patient and, 
therefore, warfarin therapy is an absolute contraindication 
to regional anesthesia.33 In St. Lucas Hospital in Tarnów 
(Poland), regional anesthesia is  given solely to  patients 
whose INR is lower than 1.2. To the best of our knowledge, 
no specific guidelines regarding anticoagulation reversal 
in patients with hip fracture have been published thus far. 
In the case of patients scheduled for elective orthopedic 
surgeries of the hip, most orthopedic surgeons follow a “wait 
and watch” policy, with discontinuation of warfarin ap-
prox. 5 days prior to the procedure in order to decrease INR 
to a subtherapeutic level.34 Similarly, no guidelines exist 
regarding bridging therapy in patients on long-term war-
farin therapy who have been qualified for a major elective 
orthopedic procedure. However, administration of LMWH 
is recommended in high-risk patients as long as their INR 
remains at a subtherapeutic level. Decision on an antico-
agulation strategy used in such group of patients should be 
made jointly by a hematologist, cardiologist, anesthesiolo-
gist, and orthopedic surgeon. In line with current guide-
lines, in patients subjected to major orthopedic surgeries, 
extended pharmacological prevention of TE with LMWH 
or another anticoagulant administered for up to 35 days 
post-procedure should be preferred over a short-term pro-
phylaxis; thromboprophylaxis should be started no later 
than within the first 12 h post-surgery.35,36 In our study, 
past history of VTE, if any, could be adequately documented 
on the basis of medical documentation.
This study is not free from potential limitations. Firstly, 
owing to the retrospective character of the analysis, a post-
operative follow-up of patients after hip and trochanteric 
surgeries was quite short (up to 35 days) and we had no ac-
cess to information on the incidence of TE or stroke after 
discharge. Therefore, it cannot be excluded that some pa-
tients with unstable anticoagulation might have experi-
enced TE shortly after cessation of the bridging. Secondly, 
pharmacological thromboprophylaxis followed the same 
protocol in all patients and, therefore, we were unable 
to analyze the potential effects of its type, duration and 
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Table 3. Characteristics of bridged patients with and without hemorrhage
Variable Bridged patients (n = 64) Bridged patients with hemorrhage (n = 19)
Bridged patients without 
hemorrhage (n = 45) p-value
Age [years] 79.50 (75.25–86.00) 84.00 (76.00–87.00) 78.00 (72.50–84.50) 0.13
Male gender, n [%] 28 (43.75) 7 (36.84) 21 (46.67) 0.59
Weight [kg] 72.00 (65.00–85.75) 72.50 (63.75–82.25) 72.00 (65.00–90.00) 0.76
Height [cm] 165.65 (±7.51) 164.78 (±6.42) 165.65 (±7.51) 0.56
BMI [kg/m²] 26.09 (23.52–30.02) 26.85 (22.86–31.81) 25.93 (23.98–29.58) 0.82
Diagnosis
Intertrochanteric fracture, n [%] 24 (37.50) 10 (52.63) 14 (31.11) 0.03
Femoral neck fracture, n [%] 24 (37.50) 9 (47.37) 15 (33.33) –
Lower leg fracture, n [%] 2 (3.13) 0 (0.00) 2 (4.44) –
Other fracture, n [%] 14 (21.88) 0 (0.00) 14 (31.11) –
Comorbidities
VTE, n [%] 1 (1.56) 0 (0.00) 1 (2.22) 1.00
AF, n [%] 56 (87.50) 19 (100.00) 37 (82.22) 0.09
Artificial heart valve, n [%] 7 (10.94) 0 (0.00) 7 (15.56) 0.09
CHD, n [%] 40 (62.50) 13 (68.42) 27 (60.00) 0.58
MI, n [%] 11 (17.19) 2 (10.53) 9 (20.00) 0.48
Stroke, n [%] 6 (9.38) 1 (5.26) 5 (11.11) 0.66
Hypertension, n [%] 51 (79.69) 14 (73.68) 37 (82.22) 0.50
DM, n [%] 9 (14.06) 3 (15.79) 6 (13.33) 1.00
Insulin, n [%] 7 (10.94) 3 (15.79) 4 (8.89) 0.42
Hyperthyroidism, n [%] 6 (9.38) 0 (0.00) 6 (13.33) 0.17
Hypothyroidism, n [%] 3 (4.69) 0 (0.00) 3 (6.67) 0.55
CKD, n [%] 4 (6.25) 2 (10.53) 2 (4.44) 0.58
COPD, n [%] 2 (3.13) 1 (5.26) 1 (2.22) 0.51
Asthma, n [%] 1 (1.56) 0 (0.00) 1 (2.22) 1.00
Superficial thrombosis, n [%] 3 (4.69) 1 (5.26) 2 (4.44) 1.00
Gastric ulcer, n [%] 3 (4.69) 2 (10.53) 1 (2.22) 0.21
Complications
PE/VTE postoperative, n [%] 4 (6.25) 0 (0.00) 4 (8.89) 0.31
MI postoperative, n [%] 1 (1.56) 0 (0.00) 1 (2.22) 1.00
ST postoperative, n [%] 1 (1.56) 1 (5.26) 0 (0.00) 0.30
SAEs postoperative, n [%] 8 (12.50) 1 (5.26) 7 (15.56) 0.42
Other complications, n [%] 4 (6.25) 0 (0.00) 4 (8.89) 0.31
Perioperative care
PRBCs, n [%] 19 (29.69) 19 (100.00) 0 (0.00) <0.001
FFP, n [%] 11 (17.19) 5 (26.32) 6 (13.33) 0.28
FFP [units] 2.00 (2.00–3.00) 2.00 (2.00–3.00) 2.00 (2.00–2.50) 0.90
Preoperative hospital stay [days] 4.00 (3.00–6.00) 4.00 (3.00–5.00) 4.00 (2.50–6.00) 0.98
Postoperative hospital stay [days] 6.00 (5.00–8.00) 7.00 (5.00–9.00) 6.00 (4.00–7.50) 0.05
Medications
VKA type – – – –
Acenocumarol, n [%] 30 (46.88) 10 (52.63) 20 (44.44) 0.60
Warfarin, n [%] 34 (53.13) 9 (47.37) 25 (55.56) –
LMWH, n [%] – – – –
Enoxaparin, n [%] 64 (100.00) 19 (100.00) 45 (100.00) –
Nadroparin, n [%] – – – –
LMWH preoperative [h] 10.5 (±4.0) 10.74 (±3.78) 10.4 (4.13) 0.76
K. Szklanny, et al. Bridging anticoagulation in orthopedics476
Variable Bridged patients (n = 64) Bridged patients with hemorrhage (n = 19)
Bridged patients without 
hemorrhage (n = 45) p-value
LMWH postoperative [h] 21 (±8) 21.47 (±7.57) 20.80 (±8.25) 0.76
LMWH postoperative [days] 32.73 (±12.53) 36.47 (±14.36) 31.16 (±11.48) 0.24
Laboratory and laboratory-based characteristics
Preoperative
INR 2.59 (1.79–3.33) 2.22 (1.64–3.31) 2.75 (1.80–3.33) 0.54
APTT [s] 36.60 (31.35–44.36) 38.20 (31.30–47.80) 36.60 (31.35–44.36) 0.76
FBG [g/L] 2.96 (2.72–3.62) 2.90 (2.46–3.40) 2.99 (2.75–3.73) 0.29
WBC [103/µL] 10.30 (8.05–13.25) 10.10 (7.20–13.80) 10.30 (8.20–13.20) 0.71
RBC [106/µL] 4.04 (3.32–4.43) 3.40 (2.76–4.03) 4.20 (3.76–4.50) 0.0004
HGB [g/dL] 11.90 (9.83–13.48) 10.40 (8.30–12.20) 12.40 (10.50–13.70) 0.0044
HCT [%] 36.75 (30.43–40.33) 30.70 (25.50–36.70) 38.00 (31.95–41.90) 0.0026

















Creatinine [µmol/L] 82.00 (63.00–108.00) 73.00 (61.00–120.00) 85.00 (69.25–104.00) 0.37
eGFR [mL/min] 78.00 (55.00–94.00) 82.50 (56.75–116.00) 72.00 (54.00–92.00) 0.29
Postoperative
INR 1.17 (1.06–1.39) 1.22 (1.04–1.36) 1.17 (1.06–1.41) 0.81
APTT [s] 30.40 (26.80–34.10) 30.40 (26.60–34.10) 30.35 (26.85–34.08) 0.99
FBG [g/L] 2.52 (2.37–2.98) 2.44 (2.22–2.99) 2.56 (2.38–2.99) 0.45
WBC [103/µL] 9.60 (7.10–12.40) 9.00 (6.30–12.40) 9.80 (7.45–13.03) 0.27
RBC [106/µL] 3.64 (3.24–4.13) 3.33 (2.79–3.55) 3.88 (3.44–4.23) 0.0013
HGB [g/dL] 10.70 (9.70–11.90) 10.00 (9.10–10.70) 11.10 (10.03–12.08) 0.0007
HCT [%] 33.00 (29.20–36.90) 30.60 (28.80–33.90) 34.75 (30.16–39.18) 0.0047
RDW [%] 15.10 (13.80–16.20) 15.50 (14.30–16.40) 15.05 (13.73–16.18) 0.36
PLT [103/µL] 198.00 (147.00–284.00) 175.00 (142.00–210.00) 222.00 (149.25–293.50) 0.08
ACEI – angiotensin-converting-enzyme inhibitors; AF – atrial fibrillation; APTT – activated partial thromboplastin time; ASA – acetylsalicylic acid;  
ARB – angiotensin receptor blockers; BMI – body mass index; CHD – coronary heart disease; CKD – chronic kidney disease; COPD – chronic obstructive 
pulmonary disease; DM – diabetes mellitus; eGFR – estimated glomerular filtration rate; FBG – fibrinogen; FFP – fresh frozen plasma; HF – heart failure;  
INR – international normalized ratio; PPIs – proton-pump inhibitors; LMWH – low molecular weight heparin; MI – myocardial infarction; NSAIDs – non-
steroidal anti-inflammatory drugs; PLT – platelets; RBC – red blood cell count; SAEs – serious adverse events; ST – stroke; VKA – vitamin K antagonist;  
VTE – venous thromboembolism; WBC – white blood cell count.
Table 3. Characteristics of bridged patients with and without hemorrhage (cont.)
anticoagulant dose on the outcome. Thirdly, due to the rel-
atively small sample size, we did not conduct subgroup 
analyses, e.g., according to specific indications for VKA 
or comorbidities. Finally, none of our subjects received 
NOACs and, consequently, application of  these agents 
in perioperative bridging of surgical orthopedic patients 
is yet to be established.
Conclusions
Periprocedural anticoagulation management in patients 
requiring urgent orthopedic procedures is a common issue 
and available evidence regarding the best practices in this 
matter is limited.
Perioperative bridging anticoagulation in orthopedic 
patients on anticoagulation therapy with VKA does not 
seem to be associated with an increase in thromboembolic 
risk nor with higher risk of bleeding.
Bridging therapy with LMWH in patients undergoing 
orthopedic procedures should be individualized to mini-
mize thromboembolic and bleeding risks in the periopera-
tive period.
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